A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Aflibercept (EYDENZELT)

Aflibercept blocks blood vessel growth to treat cancer or retinal diseases.

First FDA approval2011-11-21
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$111.8M in CY2024 Part D spend43K claims · 13K beneficiaries · 329 plans surveyed

Lowest NADAC
/unit
0 NDCs benchmarked, lowest of all strengths.
Average NADAC
Across all dosage forms in distribution.
Highest NADAC
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Aflibercept used for?

Aflibercept blocks blood vessel growth to treat cancer or retinal diseases.

Is there a generic for Aflibercept?

No. Aflibercept is brand-only with no generic equivalents currently in market.

How much does my plan pay for Aflibercept?

NADAC pricing data not currently available for this drug.

Is Aflibercept on the FDA shortage list?

No. Aflibercept is not currently on the FDA Drug Shortage Database.

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Vascular Endothelial Growth Factor Inhibitor6 alternatives in D1
01
Aflibercept-Ayyh
Brand: PAVBLU
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
02
Bevacizumab
Brand: Avastin
Lowest NADAC
0Generic mfrs
$13.1MCY24 Part D spend
Compare →
03
Bevacizumab-Adcd
Brand: Vegzelma
Lowest NADAC
0Generic mfrs
$1.5MCY24 Part D spend
Compare →
04
Bevacizumab-Awwb
Brand: MVASI
Lowest NADAC
0Generic mfrs
$26.0MCY24 Part D spend
Compare →
05
Bevacizumab-Bvzr
Brand: Zirabev
Lowest NADAC
0Generic mfrs
$15.6MCY24 Part D spend
Compare →
06
Bevacizumab-Maly
Brand: ALYMSYS
Lowest NADAC
0Generic mfrs
$5.0MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.